CIK 0001817713
- Large accelerated filer
Janux Therapeutics, Inc.
Sign in to watch- Ticker
- JANX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 822289112
- Phone
- +1 858-751-4493
- Business address
- 10955 VISTA SORRENTO PARKWAY, SUITE 200, SAN DIEGO, CA, 92130
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 38 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-06-03 | Avalon Ventures XI, L.P. 10% owner | Sale | −691,525 | $54.75 | $37.9M | 3,340,018 |
| 2024-03-04 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase · Pre-Funded Warrants (Right to Buy) | +1,397,849 | $46.50 | $65.0M | 1,397,849 |
| 2024-02-29 | Avalon Ventures XI, L.P. 10% owner | Other disposition | −438,722 | 3,948,495 | ||
| 2024-02-29 | Avalon Ventures XI, L.P. 10% owner | Other acquisition | +11,388 | 11,388 | ||
| 2024-02-29 | Avalon Ventures XI, L.P. 10% owner | Other disposition | −11,388 | 0 | ||
| 2024-02-29 | Avalon Ventures XI, L.P. 10% owner | Other disposition | −447,949 | 4,031,543 | ||
| 2024-02-29 | Avalon Ventures XI, L.P. 10% owner | Other acquisition | +31,456 | 31,456 | ||
| 2024-02-29 | Avalon Ventures XI, L.P. 10% owner | Other disposition | −31,456 | 0 | ||
| 2024-02-29 | Avalon Ventures XI, L.P. 10% owner | Other disposition | −84,985 | 764,869 | ||
| 2024-02-29 | Avalon Ventures XI, L.P. 10% owner | Other acquisition | +1,700 | 1,700 | ||
| 2024-02-29 | Avalon Ventures XI, L.P. 10% owner | Other disposition | −1,700 | 0 | ||
| 2024-02-29 | Gujrathi Sheila Director | Other acquisition | +2,986 | 108,028 | ||
| 2024-02-29 | CAPPS VICKIE L Director | Other acquisition | +1,493 | 65,543 | ||
| 2024-01-02 | Winter Charles M. Chief Technical Officer | Grant or award · Stock Option (right to buy) | +111,000 | 111,000 | ||
| 2024-01-02 | Robinson Byron Chief Strategy Officer | Grant or award · Stock Option (right to buy) | +151,500 | 151,500 | ||
| 2024-01-02 | Reardon Tighe Acting Chief Financial Officer | Grant or award · Stock Option (right to buy) | +157,000 | 157,000 | ||
| 2024-01-02 | Meyer Andrew Hollman Chief Business Officer | Grant or award · Stock Option (right to buy) | +105,000 | 105,000 | ||
| 2024-01-02 | Campbell David Alan President and CEO | Grant or award · Stock Option (right to buy) | +356,500 | 356,500 | ||
| 2024-01-02 | DiRaimondo Thomas Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +147,000 | 147,000 | ||
| 2023-11-13 | Reardon Tighe Acting Chief Financial Officer | Purchase | +849,854 | $5.87 | $5.0M | 849,854 |
Page 14 of 15 · 294 trades